Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the
            <scp>COVID</scp>
            ‐19 pandemic

Keeling, E.; Daly, S.; McKenna, D.B.

doi:10.1111/dth.13488

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In overall these group of patients may benefit more from future SARS‐Cov‐2 vaccination. Since the chronic nature of this pandemic, specialists should decide based on recent evidence with regard to case‐by case variations considering cost‐benefit ratio and also disease psychological burden 46,54,63,78,79 …”

Section: Discussionmentioning

confidence: 99%

“…regard to case-by case variations considering cost-benefit ratio and also disease psychological burden. 46,54,63,78,79 Biologic immunomodulators especially TNF-a inhibitors, janus kinase (JAK) inhibitors, anti-IL 6 (Tocilizumab) may capable to control cytokine storms and it was systemic consequences like ARDS and etc in COVID-19 course and some trials were conducted to evaluate their efficacy in disease management, so patients who are using these drugs do not be needed to disrupt. 80 Here in we discuss about experts' recommendations of management of specific cutaneous diseases during pandemic:…”

Section: Petechial Lesions Have Been Seen In Above Case and Another Omentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review

Seirafianpour

Sodagar

Mohammad

et al. 2020

Dermatologic Therapy

132

149

View full text Add to dashboard Cite

Background COVID‐19 had a great impact on medical approaches among dermatologist Objective This systematic review focuses on all skin problems related to COVID‐19, including primary and secondary COVID‐related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues Method Search was performed on PubMed, Scopus, Embase and ScienceDirect. Other additional resources were searched included Cochrane, WHO, Medscape and coronavirus dermatology resource of Nottingham university. The search completed on May/03/2020. 377 articles assigned to the inclusion and exclusion groups Result Eighty‐nine articles entered the review. Primary mucocutaneous and appendageal presentations could be the initial or evolving signs of COVID‐19. It could be manifest most commonly as a maculopapular exanthamatous or morbiliform eruption, generalized urticaria or pseudo chilblains recognized as “COVID toes” (pernio‐like acral lesions or vasculopathic rashes). Conclusion: During pandemic, Non‐infected non‐at risk patients with immune‐medicated dermatologic disorders under treatment with immunosuppressive immunomodulators are not needed to alter their regimen or discontinue the therapies. At‐risk and infection‐suspected patients needed to dose reduction, interval increase or temporary drug discontinuation (at least 2 weeks). Patients with an active COVID‐19 infection should hold the biologic or non‐biologic immunosuppressives until the complete recovery occur (at least 4 weeks). This article is protected by copyright. All rights reserved.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Petechial Lesions Have Been Seen In Above Case and Another Omentioning

confidence: 99%

Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review

Seirafianpour

Sodagar

Mohammad

et al. 2020

Dermatologic Therapy

132

149

View full text Add to dashboard Cite

show abstract

Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic review

Nobari

Goodarzi

2020

Dermatologic Therapy

View full text Add to dashboard Cite

In patients with specific dermatologic disorders who are affected by new corona virus, we know little about disease course (underlying disease and new onset infection), and the most proper management strategies include both issues that are what this systematic review targets. Databases of PubMed, Scopus, Google Scholar, Medscape, and Centre of Evidence-Based Dermatology, coronavirus dermatology resource of Nottingham University searched completely up to May 15, 2020, and initial 237 articles were selected to further review and finally 9 articles (including 12 patients) entered to this study. From 12 patients with chronic underlying dermatologic disease treated with systemic therapies, only 1 patient required Intensive Care Unit admission, the others have been treated for mild-moderate symptoms with conventional therapies. The biologic or immunosuppressive/immunomodulator agents have been ceased during the course of disease. The course of coronovirus diseases 2019 (COVID-19) and its management was as similar as normal populations. Their underlying dermatologic disease were exacerbating from mild to moderate. Their treatment has been continued as before, after the symptoms improved. Exacerbation of patients underlying dermatologic disease was mild to moderate. Discontinuing the treatment in the acute period of COVID and the restart after recovery may prevent severe recurrence and disturbing cytokine storms in these patients.

show abstract

Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID ‐19 pandemic

Cited by 2 publications

References 1 publication

Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review

Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review

Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic review

Contact Info

Product

Resources

About